Advertisement

Evidence-Based Management of the Patient with Congestive Heart Failure

  • Nicolas W. Shammas
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Treatment of heart failure starts with controlling risk factors, management of asymptomatic systolic dysfunction, and aggressive treatment of symptomatic failure with diuretics, beta blockers, ACEI (or ARB or ARNI), and aldosterone antagonists. The use of IV inotropes should be discouraged except for hemodynamic stability. Eligible patients need to receive biventricular pacing, ICD, or LVAD. Diastolic dysfunction is often a neglected cause of CHF, and diagnosis needs to be considered when CHF is present in the setting of normal left ventricular systolic function. HFNEF diagnosis is a relatively new entity that needs to be considered in the symptomatic heart failure patient.

Keywords

Congestive heart failure Echocardiography Systolic dysfunction Diastolic dysfunction Pulmonary edema 

References

  1. 1.
    Brush C. Doppler tissue analysis of mitral annular velocities: evidence for systolic abnormalities in patients with diastolic heart failure. J Am Soc Echocardiogr. 2003;16:1031–6.CrossRefGoogle Scholar
  2. 2.
    Haney S, Sur D, Xu Z. Diastolic heart failure: a review and primary care perspective. J Am Board Fam Pract. 2005;18:189–98.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Hunt SA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    O’Connell JB, Bristow M. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1993;13:S107–12.Google Scholar
  5. 5.
    Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community. A study of al incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol. 2001;87:413–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53:905–18.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart. 2003;89:49–53.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29–34.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618–26.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557–62.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3–9.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Blaufarb IS, Sonnenblick EH. The renin–angiotensin system in left ventricular remodeling. Am J Cardiol. 1996;77:8C–16C.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Solomon SD, Anavekar N, Skali H, et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738–44.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Curtis JP, Sokol SI, Wang Y, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42:736–42.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Opie LH. The neuroendocrinology of congestive heart failure. Cardiovasc J S Afr. 2002;13:171–8.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol. 2005;100:347–53.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Bauersachs J, Schafer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol. 2004;2:115–24.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Francis GS. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol. 1998;32(Suppl 1):S16–21.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Blum A, Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med. 2001;52:15–27.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(4 Suppl A):61A–71A.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Mann DL, Kent RL, Parsons B, Cooper G 4th. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Mann DL. Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive. Prog Cardiovasc Dis. 1998;41(1 Suppl 1):1–8.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Nikolaidis LA, Trumble D, Hentosz T, et al. Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MvO2 cost of catecholamines in heart failure). Eur J Heart Fail. 2004;6:409–19.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–64.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.CrossRefGoogle Scholar
  29. 29.
    Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79–87.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    van de Wal RM, Voors AA, Plokker HW, van Gilst WH, van Veldhuisen DJ. New pharmacological strategies in chronic heart failure. Cardiovasc Drugs Ther. 2004;18:491–501.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.CrossRefGoogle Scholar
  34. 34.
    Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure with emphasis on regional systolic function. Circulation. 2006;113:296–304.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function and contractility in patients with diastolic heart failure. Circulation. 2005;111:2306–12.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714–20.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Redfiled MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventrciular dysfunction in the community: appreciating the scope of heart failure epidemic. JAMA. 2003;289:194–202.CrossRefGoogle Scholar
  38. 38.
    Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123–6.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Ewy GA. Diastolic dysfunction. J Insur Med. 2004;36:292–7.PubMedPubMedCentralGoogle Scholar
  41. 41.
    de Las Fuentes L, Waggoner AD, Brown AL, Davila-Roman VG. Plasma triglyceride level is an independent predictor of altered left ventricular relaxation. J Am Soc Echocardiogr. 2005;18:1285–91.CrossRefGoogle Scholar
  42. 42.
    Kasikcioglu HA, Karasulu L, Durgun E, Oflaz H, Kasikcioglu E, Cuhadaroglu C. Aortic elastic properties and left ventricular diastolic dysfunction in patients with obstructive sleep apnea. Heart Vessel. 2005;20:239–44.CrossRefGoogle Scholar
  43. 43.
    Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96:1563–7.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Mottram PM, Short L, Baglin T, Marwick TH. Is “diastolic heart failure” a diagnosis of exclusion? Echocardiographic parameters of diastolic dysfunction in patients with heart failure and normal systolic function. Heart Lung Circ. 2003;12:127–34.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Lim TK, Ashrafian H, Dwivedi G, Collinson PO, Senior R. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure. Eur J Heart Fail. 2006;8:38–45.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Qu P, Ding Y, Xia D, Wang H, Tian X. Variations in cardiac diastolic function in hypertensive patients with different left ventricular geometric patterns. Hypertens Res. 2001;24(5):601–4.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Morris SA, Van Swol M, Udani B. The less familiar side of heart failure: symptomatic diastolic dysfunction. J Fam Pract. 2005;54:501–11.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–e82.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 2000;45:813–25.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Chang NC, Shih CM, Bi WF, Lai ZY, Lin MS, Wang TC. Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovasc Drugs Ther. 2002;16:141–7.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Yip GWK, Wang M, Wang T, Chan S, Fung JWH, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573–80.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Roongsritong C, Sutthiwan P, Bradley J, Simoni J, Power S, Meyerrose GE. Spironolactone improves diastolic function in the elderly. Clin Cardiol. 2005;28:484–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    The J-ELAN Investigators. Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN). Circ J. 2006;70:124–8.CrossRefGoogle Scholar
  55. 55.
    Yamamoto K, Ozaki H, Takayasu K, Akehi N, Fukui S, Sakai A, Kodama M, Shimonagata T, Kobayashi K, Ota M, Horiguchi Y, Ebisuno S, Katsube Y, Yamazaki T, Ohtsu H, Hori M. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res. 2011;34:325–30.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Bajraktari G, Koltai MS, Ademaj F, et al. Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006;110:206–11.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Charvat J, Michalova K, Chlumsky J, Valenta Z, Kvapil M. The association between left ventricle diastolic dysfunction and endothelial dysfunction and the results of stress myocardial SPECT in asymptomatic patients with type 2 diabetes. J Int Med Res. 2005;33:473–82.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Grandi AM, Piantanida E, Franzetti I, et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol. 2006;97:71–6.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Komajda M, Hanon O, Hochadel M, Follath F, Swedberg K, Gitt A, Cleland JG. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J. 2007;28:1310–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Rodeheffer RJ. The new epidemiology of heart failure. Curr Cardiol Rep. 2003;5:181–6.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–82.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J. 2004;148:883–8.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Das SR, Dries DL, Drazner MH, Yancy CW, Chae CU. Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial). Am J Cardiol. 2005;96:827–31.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88(5 Pt 1):2277–83.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–91.CrossRefGoogle Scholar
  69. 69.
    Eisenberg MJ, Gioia LC. Angiotensin II receptor blockers in congestive heart failure. Cardiol Rev. 2006;14:26–34.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Prasad SK, Dargie HJ, Smith GC, et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart. 2006;92:798–803.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Zareba W, Piotrowicz K, McNitt S, Moss AJ, MADIT II Investigators. Implantable cardioverter–defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol. 2005;95:1487–91.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Moss AJ. MADIT-I and MADIT-II. J Cardiovasc Electrophysiol. 2003;14(9 Suppl):S96–8.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefGoogle Scholar
  74. 74.
    ACC/AHA 2005 Guideline Update. Diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112:e154–235.CrossRefGoogle Scholar
  75. 75.
    CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35.CrossRefGoogle Scholar
  76. 76.
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefGoogle Scholar
  77. 77.
    Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573–81.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol. 1993;22(4 Suppl A):158A–61A.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    AIRE Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–8.Google Scholar
  80. 80.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–6.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin–converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80–5.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–52.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–7.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414–21.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Wong M, Staszewsky L, Latini R, et al. Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–5.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Young JB. The global epidemiology of heart failure. Med Clin North Am. 2004;88:1135–43.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Yusuf S, Ostergren JB, Gerstein HC, et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005;112:48–53.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110:2180–3.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Doggrell SA. ACE inhibitors or AT-1 antagonists—which is OPTIMAAL after acute myocardial infarction? Expert Opin Pharmacother. 2003;4:407–9.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752–60.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Moller JE, Dahlstrom U, Gotzsche O, et al. OPTIMAAL Study Group. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy. Am Heart J. 2004;147:494–501.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–97.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Deswal A, Yao D. Aldosterone receptor blockers in the treatment of heart failure. Curr Treat Options Cardiovasc Med. 2004;6:327–34.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108:1306–9.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998–2001. Circulation. 2005;112:39–47.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.CrossRefGoogle Scholar
  101. 101.
    Study Group MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;253:2001–7.Google Scholar
  102. 102.
    Investigators CIBIS-II. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.CrossRefGoogle Scholar
  103. 103.
    Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. US Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001;37:1692–9.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57–66.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Yancy CW, Fowler MB, Colucci WS, et al. US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358–65.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The US Carvedilol Heart Failure Study Group. J Card Fail. 1997;3:173–9.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Krum H, Roecker EB, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–8.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Janosi A, Ghali JK, Herlitz J, et al. MERIT-HF Study Group. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J. 2003;146:721–8.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    CIBIS-II Investigators. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J. 2001;22:1021–31.CrossRefGoogle Scholar
  111. 111.
    Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. Am Heart J. 2005;149:370–6.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.CrossRefPubMedGoogle Scholar
  113. 113.
    Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–3226.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Lenzen MJ, Boersma E, Reimer WJ, et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J. 2005;26:2706–13.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147:324–30.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807–16.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Majumdar SR, McAlister FA, Cree M. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Clin Ther. 2004;26:694–703.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Failure Society of America. J Am Coll Cardiol. 2016:[Epub ahead of print].Google Scholar
  119. 119.
    Wade OL. Digoxin 1785–1985. I. Two hundred years of digitalis. J Clin Hosp Pharm. 1986;11:3–9.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525–33.CrossRefGoogle Scholar
  121. 121.
    Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Lader E, Egan D, Hunsberger S, Garg R, Czajkowski S, McSherry F. The effect of digoxin on the quality of life in patients with heart failure. J Card Fail. 2003;9:4–12.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15:2195–203.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Shammas NW, Harris ML, McKinney D, Hauber WJ. Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clin Cardiol. 2001;24:786–7.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22:955–62.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677–83.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Leon AR, Abraham WT, Curtis AB, et al. MIRACLE Study Program. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol. 2005;46:2348–56.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Leon AR, Abraham WT, Brozena S, et al. InSync III Clinical Study Investigators. Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol. 2005;46:2298–304.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol. 2005;12:107–13.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.CrossRefGoogle Scholar
  133. 133.
    Moss AJ, Daubert J, Zareba W. MADIT-II: clinical implications. Card Electrophysiol Rev. 2002;6:463–5.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Moss AJ, Greenberg H, Case RB, et al. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760–5.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Moss AJ, Brown MW, Cannom DS, et al. Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol. 2005;10(4 Suppl):34–43.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Naughton MT. The link between obstructive sleep apnea and heart failure: underappreciated opportunity for treatment. Curr Cardiol Rep. 2005;7:211–5.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    O’Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11:200–5.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Levine BS. Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure. J Cardiovasc Nurs. 2000;14:76–93.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001;142:393–401.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Abraham WT, Cheng ML, Smoluk G, Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Study Group. Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. Congest Heart Fail. 2005;11:59–64.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Burger AJ, Horton DP, LeJemtel T, et al. Prospective randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102–8.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155–62.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–40.Google Scholar
  147. 147.
    Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med. 2005;23:327–31.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol. 2004;94:595–601.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–5.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435–43.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Stevenson LW, Miller LW, Desvigne-Nickens P, et al. REMATCH Investigators. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. 2004;110:975–81.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail. 2005;11:133–8.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Francis GS. Pathophysiology of chronic heart failure. Am J Med. 2001;110(Suppl 7A):37S–46S.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicolas W. Shammas
    • 1
  1. 1.Midwest Cardiovascular Research FoundationDavenportUSA

Personalised recommendations